Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
USD $4.5 million co-funding agreement for Parkinson’s research renewed
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports collaborative Parkinson’s clinical trials, has been renewed for a further three years.
The role of faulty cell protein in Parkinson’s
A process called m6A mRNA methylation is reduced in people with Parkinson’s. Research is underway to develop drugs that can improve this protein production process.
New biotech company focused on cell transplantation for Parkinson’s
Biotech company Ryne Bio has received a large research grant from CIRM to develop their late-stage preclinical cell transplantation procedure for Parkinson’s.
Sun Pharma shines on c-ABL
Sun Pharma have published data on their new drug vodobatinib which is a c-ABL inhibitor – c-ABL is over-active in the brains of people with Parkinson’s.
Biotech Inhibikase develops new drug for Parkinson’s
Researchers have published laboratory data demonstrating the neuroprotective effects of a new potential drug for Parkinson’s called IkT-148009.